Wave Life Sciences Slips as Obesity Data Fails to Convince

Core Viewpoint - Wave Life Sciences' shares have plummeted nearly 50% following price target cuts from BofA and Wells Fargo, indicating concerns over the efficacy of its obesity candidate WVE-007 as a standalone treatment [2][6]. Price Target Adjustments - BofA reduced its price target for WVE to $21 from $38 while maintaining a Buy rating, citing the need for more evidence to support WVE-007's potential, especially as a monotherapy [3]. - Wells Fargo lowered its target to $13 from $27, keeping an Overweight rating, but expressed reduced confidence in the liver Activin E knockdown mechanism's ability to drive significant fat loss [4]. Trial Data Insights - The INLIGHT trial reported a 14.3% placebo-adjusted reduction in visceral fat after six months, with preservation of lean muscle mass, which is a differentiating factor compared to GLP-1 therapies [5]. - Earlier data indicated an 85% mean reduction in Activin E at the 400mg dose; however, the market's reaction suggests that this biomarker suppression did not lead to the expected fat loss [5][6]. Efficacy Concerns - The Phase 1 cohort of the INLIGHT trial included lower-BMI patients, raising questions about the efficacy of WVE-007 as a monotherapy in the population most likely to benefit from obesity treatments [6].